Literature DB >> 17340669

Chiral platinum(II) metallointercalators with potent in vitro cytotoxic activity.

Dianne M Fisher1, Patrick J Bednarski, Renate Grünert, Peter Turner, Ronald R Fenton, Janice R Aldrich-Wright.   

Abstract

Four platinum(II) metallointercalating complexes of 1,10-phenanthroline (phen) with the chiral ancillary ligands trans-R,R- and trans-S,S-1,2-diaminocyclohexane (R,R- and S,S-dach, respectively), and N,N'-dimethyl-R,R- and N,N'-dimethyl-S,S-1,2-diaminocyclohexane (Me(2)-R,R-dach and Me(2)-S,S-dach, respectively) have been synthesised and characterised. The crystal structure of [Pt(Me(2)-S,S-dach)(phen)](ClO(4))(2)1.5 H(2)O (C(20)H(26)Cl(2)N(4)O(9.5)Pt) has been determined; orthorhombic, space group P2(1)2(1)2(1)(No. 19), a=23.194(8), b=25.131(9), c=8.522(3) A. In vitro cytotoxic assays (IC(50)) in the human bladder cancer cell line 5637 and in the murine leukemia L1210 cell line revealed that [Pt(S,S-dach)(phen)](ClO(4))(2) (0.091 and 0.13 microM, respectively) and [Pt(R,R-dach)(phen)](ClO(4))(2) (0.54 and 1.50 microM, respectively) were more cytotoxic than cisplatin (0.31 and 0.50 microM, respectively) and considerably more cytotoxic than their methylated counterparts, [Pt(Me(2)-R,R-dach)(phen)](ClO(4))(2) and [Pt(Me(2)-S,S-dach)(phen)](ClO(4))(2) (both>23 microM). Chiral discrimination for [Pt(S,S-dach)(phen)](ClO(4))(2) over its R,R-enantiomer was observed in all 13 cancer cell lines investigated. Moreover, [Pt(S,S-dach)(phen)](ClO(4))(2) was more active than cisplatin in all cell lines tested and shows only partial cross-resistance to cisplatin in two cisplatin resistant cell lines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17340669     DOI: 10.1002/cmdc.200600211

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  8 in total

1.  Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator.

Authors:  Johnny Moretto; Bruno Chauffert; François Ghiringhelli; Janice R Aldrich-Wright; Florence Bouyer
Journal:  Invest New Drugs       Date:  2010-06-10       Impact factor: 3.850

Review 2.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

3.  Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator.

Authors:  Shaoyu Wang; Vincent J Higgins; Janice R Aldrich-Wright; Ming J Wu
Journal:  J Chem Biol       Date:  2011-12-06

4.  A dual-targeting, p53-independent, apoptosis-inducing platinum(II) anticancer complex, [Pt(BDI(QQ))]Cl.

Authors:  Kogularamanan Suntharalingam; Justin J Wilson; Wei Lin; Stephen J Lippard
Journal:  Metallomics       Date:  2014-02-11       Impact factor: 4.526

5.  Encapsulation of platinum(II)-based DNA intercalators within cucurbit[6,7,8]urils.

Authors:  Sharon Kemp; Nial J Wheate; Shaoyu Wang; J Grant Collins; Stephen F Ralph; Anthony I Day; Vincent J Higgins; Janice R Aldrich-Wright
Journal:  J Biol Inorg Chem       Date:  2007-07-25       Impact factor: 3.358

6.  Spectroscopic investigations on the interactions of potent platinum(II) anticancer agents with bovine serum albumin.

Authors:  Anwen M Krause-Heuer; William S Price; Janice R Aldrich-Wright
Journal:  J Chem Biol       Date:  2012-05-11

7.  A Systems Biology Approach to Understanding the Mechanisms of Action of an Alternative Anticancer Compound in Comparison to Cisplatin.

Authors:  Elise P Wright; Matthew P Padula; Vincent J Higgins; Janice R Aldrich-Wright; Jens R Coorssen
Journal:  Proteomes       Date:  2014-11-10

8.  Use of Half-Generation PAMAM Dendrimers (G0.5-G3.5) with Carboxylate End-Groups to Improve the DACHPtCl2 and 5-FU Efficacy as Anticancer Drugs.

Authors:  Cláudia Camacho; Helena Tomás; João Rodrigues
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.